Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

Concerns about the company's future growth are likely keeping investors away.

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...